Nanobiotix on its way to change the paradigm in cancer therapy

08/01/2015 - 4 minutes

Nanobiotix is an oncology focused nanomedicine company developing an innovative nanoparticle technology. Their NanoXray technology comprises three products having the potential to cause a paradigm shift in cancer therapy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell.

The following video is showing how this disruptive technology is acting in the patient’s body.

Please accept preferences cookies to watch this video.
The Company made major clinical and financial progress, including broadening of indications and strategic plans across Europe, Asia and the US.

NBTXR3 flagship of the clinical development

The company is developing three different products that can be administered either by direct injection into the tumor (NBTXR3), intravenous injection (NBTX-IV) or topical application to fill tumor cavities just after tumor surgery (NBTX-TOPO). NBTXR3 is the first product of the NanoXray portfolio to reach clinical development. The product comprises nanoparticles which can be injected directly into tumor. With the application of radiotherapy, these nanoparticles absorb X-rays which significantly enhances the radiation dose within the cancer cells without increasing the dose to the surrounding healthy tissues.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!